Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of ...
"We've lost too many student-athletes to heart conditions discovered too late," said Sen. Saud Anwar, D-South Windsor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results